Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Sep 08, 2021

India Pharma Sector - IPM Growth On An Uptrend In August Led By Select Therapies: Motilal Oswal

India Pharma Sector - IPM Growth On An Uptrend In August Led By Select Therapies: Motilal Oswal
A person holding colourful capsules strips for photograph. (Photograph: Bloomberg)
STOCKS IN THIS STORY
Ajanta Pharma Ltd.
--
Zydus Wellness Ltd.
--
Ipca Laboratories Ltd.
--
Natco Pharma Ltd.
--
FDC Ltd.
--
Novartis India Ltd.
--
JB Chemicals & Pharmaceuticals Ltd.
--
Cipla Ltd.
--
Pfizer Ltd.
--
Sanofi Consumer Healthcare India Ltd
--
Eris Lifesciences Ltd.
--
Lupin Ltd.
--
Alkem Laboratories Ltd.
--
Sun Pharmaceutical Industries Ltd.
--
Glaxosmithkline Pharmaceuticals Ltd.
--
Alembic Pharmaceuticals Ltd.
--
Indoco Remedies Ltd.
--
Abbott India Ltd.
--
Glenmark Pharmaceuticals Ltd.
--
Torrent Pharmaceuticals Ltd.
--

BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

India pharma market growth was 17.7% YoY in August 2021 versus 13.7 % YoY in July 2021.

Respiratory/analgesics/anti-infectives grew 38.2%/32.4%/29.2% YoY.

Respiratory sales growth increased sequentially, with 38.2% YoY growth achieved in August-21 (versus 22.8% YoY growth in July-21).

For the quarter ended August-21, YoY growth stood at 15.2% YoY.

Price growth of 5.8% YoY and new product growth of 3.5% YoY was further boosted by 5.9% YoY volume growth.

Click on the attachment to read the full report:

Motilal Oswal Pharma Monthly Update.pdf
VIEW DOCUMENT

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search